What type of study is this?

This is a Pre-Registered Trial study.

What question did this study set out to answer?

This trial investigates the efficacy and safety of sonrotoclax combined with obinutuzumab in treatment-naive CLL patients.

December 8, 2025Blood

View Full Paper

Ask AI

Bookmark

This trial investigates the efficacy and safety of sonrotoclax combined with obinutuzumab in treatment-naive CLL patients.
Conducted a phase 1/1b, dose-escalation study in treatment-naive CLL patients.
Administered obinutuzumab and then sonrotoclax with specific dosing schedules over multiple treatment cycles.
Assessed safety and efficacy through response rates and minimal residual disease evaluations.
Of 55 enrolled patients, 89% overall response rate and 46% complete response rates were observed.
High rates of minimal residual disease (<1 CLL cell per 10,000 leukocytes) were achieved early in treatment.
The maximum tolerated dose was not reached, and adverse events were manageable.

No takes yet. Share an insight, caveat, or question.

Phase 1 trial reports high rates of minimal residual disease and overall response in treatment-naive CLL using sonrotoclax and obinutuzumab.

Ma et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark

Phase 1 trial reports high rates of minimal residual disease and overall response in treatment-naive CLL using sonrotoclax and obinutuzumab.